In patients with metastatic melanoma, response to 2nd line single agent anti-PD-1 after 1st line palliative TT is ~25%.19 This is significantly less than the RR of 37% seen in the 1st line setting in BRAF mutant patients. The gene discussed is BRAF; the disease is metastatic melanoma.